Increasing Clinical Studies on Attention Deficit Hyperactivity Disorder (ADHD) Drugs with the regulatory approval of ADHD Drugs is Boosting the Market

ABOUT THIS REPORT

OVERVIEW

Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market was valued at $17.2 billion in 2019 with a CAGR of 6.3% from 2020 to 2026.

Attention Deficit Hyperactivity Disorder (ADHD) drugs are used for the treatment of attention deficit hyperactivity disorder (ADHD). Some of the medications for ADHD include methylphenidate, Dexamfetamine, lisdexamfetamine, atomoxetine, guanfacine, and others. The medications help with the condition concentrate better, be less impulsive, feel calmer, and learn and practice new skills.

The rising prevalence of attention deficit hyperactivity disorder is a key driving factor in the market. For instance, according to the Centers for Disease Control and Prevention (CDC), the prevalence of adult attention deficit hyperactivity disorder (ADHD) is estimated at 2.8% globally. More than 6.1 million children in the United States age between 2 to 17 are estimated to have ADHD in 2017, of which 388,000 of young children are aged between 2 to 5 years, 2.4 million of children are aged between 6 to 11 years, and 3.3 million of children are aged between 12 to 17 years. According to the Attention Deficit Disorder Association, 11 million adults in the U.S. have attention deficit hyperactivity disorder (ADHD). Further, increasing clinical studies for attention deficit hyperactivity disorder (ADHD) drugs is driving the market demand. For instance, Otsuka Pharmaceutical Development & Commercialization, Inc., has completed phase 3 clinical trials for the efficacy, safety, and tolerability of oral centanafadine. centanafadine is a novel investigational compound for the treatment of the adult with attention-deficit hyperactivity disorder (ADHD).

Stimulants (Methylphenidate, Dextroamphetamine, Amphetamine, and Others) and Non-Stimulants (Atomoxetine, Guanfacine, Bupropion, and Others) is the type segment of the market scope. By distribution channel, the market is divided into Hospital Pharmacies, Retail Pharmacies, Speciality Clinics, and e-Commerce. The report covers the value of the global market by type and distribution channel.

Stimulant accounted for the largest share in the attention deficit hyperactivity disorder (ADHD) drugs market in 2019 and is expected to dominance in the forecast period. The increasing clinical studies on attention deficit hyperactivity disorder (ADHD) drugs, and government support for the use of stimulants ADHD drugs in the treatment of attention deficit hyperactivity disorder (ADHD), and regulatory approval of attention deficit hyperactivity disorder (ADHD) drugs are some of the factors driving the market demand.

North America, Europe, Asia Pacific, South America, and Middle East & Africa are taken into consideration at the global attention deficit hyperactivity disorder (ADHD) drugs value figures. While North America is further categorized into enhancing the United States, Canada, and Mexico, Europe is split into the United Kingdom, Germany, France, Italy, and Rest of Europe. Asia-Pacific covers India, China, Japan, South Korea, and Rest of Asia Pacific in its scope. South America is bifurcated into Brazil, Argentina, and Rest of South America, with Middle East & Africa involving GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the attention deficit hyperactivity disorder (ADHD) drugs market in 2019, owing to the rising incidence of ADHD, research and development activity for ADHD drugs, and commercialization of regulatory approved ADHD drugs.

Major players operating in the attention deficit hyperactivity disorder (ADHD) drugs industry include Novartis AG, Pfizer, Eli Lily & Company, Johnson & Johnson Services, LLC, Lupin, Purdue Pharma L.P., GlaxoSmithKline PLC, Hisamitsu Pharmaceutical Co., Inc., and Mallinckrodt, UCB S.A.

The development of attention deficit hyperactivity disorder (ADHD) drugs with the wider application by the companies, commercialization of regulatory approved ADHD drugs, rising clinical studies on ADHD drugs, and the collaboration between companies to develop attention deficit hyperactivity disorder (ADHD) drugs and expand the market presence are some of the strategies adopted by the prominent players.